Stay updated on IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.

Latest updates to the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content changes regarding a clinical study for IMMU-132 in triple-negative breast cancer, with the removal of detailed study information and the addition of a new version number.SummaryDifference31%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check88 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check109 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IMMU-132+Carboplatin in Triple-Negative Breast Cancer Clinical Trial page.